Phase 3, single-center, sequential and parallel-group, double-blind, randomized study evaluating the efficacy and safety of Fexofenadine Hydrochloride 180 mg (Allegra®/Telfast®) versus placebo in subjects suffering from seasonal Allergic Rhinitis with symptoms aggravated in presence of pollutants

Phase 3, single-center, sequential and parallel-group, double-blind, randomized study evaluating the efficacy and safety of Fexofenadine Hydrochloride 180 mg (Allegra®/Telfast®) versus placebo in subjects suffering from seasonal Allergic Rhinitis with symptoms aggravated in presence of pollutants

Bibliographic Details
Main Authors: Anne K. Ellis, Margarita Murrieta-Aguttes, Sandy Furey, Christopher Carlsten
Format: Article
Language:English
Published: Elsevier 2020-08-01
Series:World Allergy Organization Journal
Online Access:http://www.sciencedirect.com/science/article/pii/S1939455120301708

Similar Items

Similar Items